Related Experiment Videos
[Ocular herpes. Therapeutic aspects (author's transl)]
La Nouvelle Presse Medicale
|September 30, 1978
Summary
Ocular herpes treatment is challenging due to viral effects and immune responses. Current antivirals (5 iodo 2'deoxyuridine, vidarabine, trifluorothymidine) are limited in deep infections and toxic to the cornea, necessitating combination therapies.
Area of Science:
- Ophthalmology
- Virology
- Immunology
Context:
- Ocular herpes presents complex treatment challenges.
- Viral activity and local immune responses impede therapeutic efficacy.
- Existing antiviral drugs show limitations in treating deep ocular infections.
Purpose:
- To review current treatment strategies for ocular herpes.
- To evaluate the effectiveness and limitations of antiviral and corticosteroid therapies.
- To discuss the role of surgery in managing sequelae of ocular herpes.
Summary:
- Current antiviral agents like 5 iodo 2'deoxyuridine, vidarabine, and trifluorothymidine are effective for superficial ocular herpes but have limited impact on stromal and uveal forms.
- These antivirals exhibit toxicity to the corneal epithelium and do not prevent recurrences, highlighting the need for alternative approaches.
- Alternating or combined use of corticosteroids and antiviral agents is often necessary, with surgery reserved for treating established sequelae.
Impact:
- Highlights the limitations of current antiviral treatments for ocular herpes.
- Emphasizes the need for combination therapies involving corticosteroids and antivirals.
- Underscores the importance of surgical intervention for managing long-term complications of ocular herpes.